On Tuesday, August 4, 2026, Moderna said it had started a phase-1 human trial in Canada for an experimental Ebola vaccine. The vaccine uses mRNA, a strip of genetic material that tells cells to make a harmless piece of the virus so the immune system learns to fight it.
The shot targets the Bundibugyo strain, the version behind Congo's worst Ebola outbreak on record. It is the second candidate for that strain to reach human testing. The trial is early-stage, known as phase 1, and uses a single dose in about 80 healthy adults. Moderna expects early safety and immune-response results in the next few months.
Money is behind the science. The Coalition for Epidemic Preparedness Innovations, a global group that funds vaccine research, is paying up to $50 million for the program. That covers the phase-1 trial and makes extra doses in parallel, so larger trials can start quickly if early results look good.
The speed makes sense with the numbers. Congo's outbreak has grown to 3,802 confirmed cases as of Sunday, and confirmed deaths stand at 1,707. That death count doubled in a little over two weeks, and officials say the current outbreak is larger than any that emerged after the 2013-16 West Africa epidemic.
The disease has also reached a fifth province in the country. The official totals come with a data note: figures for May 15-16 and June 26 were not available, and the July 22 increase came from combining provincial and national tracking records, not only from new cases and deaths.
Get the free Always Be Buying eBook and learn the simple system for building wealth on any income
That context matters because the gap in protection is real. Merck's Ervebo is a licensed vaccine for the Zaire strain, the version tied to Congo's earlier large outbreak and the 2013-16 West Africa epidemic, but it is not approved for Bundibugyo. At least 46 health workers have died, and no licensed vaccine or treatment exists for the strain they are fighting.
For that reason, the Africa Centres for Disease Control and Prevention and its partners will request this week that a World Health Organization panel of advisers weigh Ervebo for health workers on the front lines. Other candidates are also moving through the pipeline.
Oxford University's vaccine, which uses an adenovirus as the delivery vehicle, entered phase-1 testing last month. Merck and partners are also readying a third Bundibugyo vaccine, built on the same technology as Ervebo, for human trials later this year.
CEPI's chief executive, Richard Hatchett, said the speed of Moderna's trial matters. "Getting Moderna's vaccine candidate into a phase-1 trial this rapidly is a major step forward in the fight against this deadly outbreak," he said.
If the Moderna shot passes the tests and wins approval, the company would supply at least 500,000 doses to low- and middle-income countries under access-pricing terms. That means the next few months are not just about lab results.
Vaccine development is a step-by-step process. Making extra doses in parallel means larger studies can begin quickly if early results look good, and CEPI's $50 million plus Moderna's access-pricing pledge for 500,000 doses show how far the response is being pushed ahead of final data.
For most people a long way from the outbreak, this is not a reason to panic. It is a reason to watch what happens next.
A rare strain with no licensed vaccine is exactly the kind of problem that turns into a bigger one when the world is slow to react. This time, the world is not waiting.
There are now multiple candidates moving through early testing, and an outside funder is paying to make extra doses before the results are final. If that bet pays off, local outbreaks would have a shorter window to turn into global events.
That is what a growing vaccine pipeline protects: not just people in outbreak zones, but everyone else who depends on the world staying open and running. It is easy to tune out a disease on the other side of the planet.
Download the free Always Be Buying eBook and start putting your money to work today